Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2016 | Pages:
1321 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2016, provides an overview of the Glioblastoma Multiforme (GBM) (Oncology) pipeline landscape. Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor. GBMs arise from glial cells, which are cells that form the tissue that surrounds and protects other nerve cells found within the brain and spinal cord. GBMs are mainly composed of star-shaped glial cells known as astrocytes. Signs and symptoms include slowly progressive neurologic deficit, usually motor weakness, headache, generalized symptoms of increased intracranial pressure, including headaches, nausea and vomiting, and cognitive impairment and seizures. Treatment includes radiation therapy and chemotherapy. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Glioblastoma Multiforme (GBM) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Glioblastoma Multiforme (GBM) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Glioblastoma Multiforme (GBM) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 11, 98, 53, 1, 4, 147, 18 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 8, 12, 1, 35 and 8 molecules, respectively. Glioblastoma Multiforme (GBM) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Glioblastoma Multiforme (GBM) (Oncology). - The pipeline guide reviews pipeline therapeutics for Glioblastoma Multiforme (GBM) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Glioblastoma Multiforme (GBM) (Oncology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Glioblastoma Multiforme (GBM) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Glioblastoma Multiforme (GBM) (Oncology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Glioblastoma Multiforme (GBM) (Oncology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Glioblastoma Multiforme (GBM) (Oncology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 Introduction 10 Glioblastoma Multiforme (GBM) Overview 11 Therapeutics Development 12 Glioblastoma Multiforme (GBM) - Therapeutics under Development by Companies 14 Glioblastoma Multiforme (GBM) - Therapeutics under Investigation by Universities/Institutes 32 Glioblastoma Multiforme (GBM) - Pipeline Products Glance 35 Glioblastoma Multiforme (GBM) - Products under Development by Companies 39 Glioblastoma Multiforme (GBM) - Products under Investigation by Universities/Institutes 61 Glioblastoma Multiforme (GBM) - Companies Involved in Therapeutics Development 65 Glioblastoma Multiforme (GBM) - Therapeutics Assessment 260 Drug Profiles 302 Glioblastoma Multiforme (GBM) - Dormant Projects 1242 Glioblastoma Multiforme (GBM) - Discontinued Products 1259 Glioblastoma Multiforme (GBM) - Product Development Milestones 1262 Appendix 1278
List of Tables
Number of Products under Development for Glioblastoma Multiforme (GBM), H2 2016 54 Number of Products under Development for Glioblastoma Multiforme (GBM) - Comparative Analysis, H2 2016 55 Number of Products under Development by Companies, H2 2016 57 Number of Products under Development by Companies, H2 2016 (Contd..1) 58 Number of Products under Development by Companies, H2 2016 (Contd..2) 59 Number of Products under Development by Companies, H2 2016 (Contd..3) 60 Number of Products under Development by Companies, H2 2016 (Contd..4) 61 Number of Products under Development by Companies, H2 2016 (Contd..5) 62 Number of Products under Development by Companies, H2 2016 (Contd..6) 63 Number of Products under Development by Companies, H2 2016 (Contd..7) 64 Number of Products under Development by Companies, H2 2016 (Contd..8) 65 Number of Products under Development by Companies, H2 2016 (Contd..9) 66 Number of Products under Development by Companies, H2 2016 (Contd..10) 67 Number of Products under Development by Companies, H2 2016 (Contd..11) 68 Number of Products under Development by Companies, H2 2016 (Contd..12) 69 Number of Products under Development by Companies, H2 2016 (Contd..13) 70 Number of Products under Development by Companies, H2 2016 (Contd..14) 71 Number of Products under Development by Companies, H2 2016 (Contd..15) 72 Number of Products under Development by Companies, H2 2016 (Contd..16) 73 Number of Products under Investigation by Universities/Institutes, H2 2016 74 Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 75 Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 76 Comparative Analysis by Late Stage Development, H2 2016 77 Comparative Analysis by Clinical Stage Development, H2 2016 78 Comparative Analysis by Early Stage Development, H2 2016 79 Comparative Analysis by Unknown Stage Development, H2 2016 80 Products under Development by Companies, H2 2016 81 Products under Development by Companies, H2 2016 (Contd..1) 82 Products under Development by Companies, H2 2016 (Contd..2) 83 Products under Development by Companies, H2 2016 (Contd..3) 84 Products under Development by Companies, H2 2016 (Contd..4) 85 Products under Development by Companies, H2 2016 (Contd..5) 86 Products under Development by Companies, H2 2016 (Contd..6) 87 Products under Development by Companies, H2 2016 (Contd..7) 88 Products under Development by Companies, H2 2016 (Contd..8) 89 Products under Development by Companies, H2 2016 (Contd..9) 90 Products under Development by Companies, H2 2016 (Contd..10) 91 Products under Development by Companies, H2 2016 (Contd..11) 92 Products under Development by Companies, H2 2016 (Contd..12) 93 Products under Development by Companies, H2 2016 (Contd..13) 94 Products under Development by Companies, H2 2016 (Contd..14) 95 Products under Development by Companies, H2 2016 (Contd..15) 96 Products under Development by Companies, H2 2016 (Contd..16) 97 Products under Development by Companies, H2 2016 (Contd..17) 98 Products under Development by Companies, H2 2016 (Contd..18) 99 Products under Development by Companies, H2 2016 (Contd..19) 100 Products under Development by Companies, H2 2016 (Contd..20) 101 Products under Development by Companies, H2 2016 (Contd..21) 102 Products under Investigation by Universities/Institutes, H2 2016 103 Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 104 Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 105 Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 106 Glioblastoma Multiforme (GBM) - Pipeline by AbbVie Inc, H2 2016 107 Glioblastoma Multiforme (GBM) - Pipeline by Activartis Biotech GmbH, H2 2016 108 Glioblastoma Multiforme (GBM) - Pipeline by Advanced Accelerator Applications SA, H2 2016 109 Glioblastoma Multiforme (GBM) - Pipeline by Advantagene Inc, H2 2016 110 Glioblastoma Multiforme (GBM) - Pipeline by Advenchen Laboratories LLC, H2 2016 111 Glioblastoma Multiforme (GBM) - Pipeline by Affimed GmbH, H2 2016 112 Glioblastoma Multiforme (GBM) - Pipeline by Agenus Inc, H2 2016 113 Glioblastoma Multiforme (GBM) - Pipeline by Amal Therapeutics SA, H2 2016 114 Glioblastoma Multiforme (GBM) - Pipeline by Ambrx Inc, H2 2016 115 Glioblastoma Multiforme (GBM) - Pipeline by Amgen Inc, H2 2016 116 Glioblastoma Multiforme (GBM) - Pipeline by Ampio Pharmaceuticals Inc, H2 2016 117 Glioblastoma Multiforme (GBM) - Pipeline by AngioChem Inc, H2 2016 118 Glioblastoma Multiforme (GBM) - Pipeline by Apac Biotech Pvt Ltd, H2 2016 119 Glioblastoma Multiforme (GBM) - Pipeline by Apceth GmbH & Co KG, H2 2016 120 Glioblastoma Multiforme (GBM) - Pipeline by APIM Therapeutics AS, H2 2016 121 Glioblastoma Multiforme (GBM) - Pipeline by Apogenix GmbH, H2 2016 122 Glioblastoma Multiforme (GBM) - Pipeline by Ariad Pharmaceuticals Inc, H2 2016 123 Glioblastoma Multiforme (GBM) - Pipeline by Arog Pharmaceuticals Inc, H2 2016 124 Glioblastoma Multiforme (GBM) - Pipeline by Astellas Pharma Inc, H2 2016 125 Glioblastoma Multiforme (GBM) - Pipeline by AstraZeneca Plc, H2 2016 126 Glioblastoma Multiforme (GBM) - Pipeline by Athenex Inc, H2 2016 127 Glioblastoma Multiforme (GBM) - Pipeline by Axelar AB, H2 2016 128 Glioblastoma Multiforme (GBM) - Pipeline by Basilea Pharmaceutica Ltd, H2 2016 129 Glioblastoma Multiforme (GBM) - Pipeline by Batu Biologics Inc, H2 2016 130 Glioblastoma Multiforme (GBM) - Pipeline by Bayer AG, H2 2016 131 Glioblastoma Multiforme (GBM) - Pipeline by BeiGene Ltd, H2 2016 132 Glioblastoma Multiforme (GBM) - Pipeline by Bexion Pharmaceuticals LLC, H2 2016 133 Glioblastoma Multiforme (GBM) - Pipeline by BeyondSpring Pharmaceuticals Inc, H2 2016 134 Glioblastoma Multiforme (GBM) - Pipeline by Bio-Path Holdings Inc, H2 2016 135 Glioblastoma Multiforme (GBM) - Pipeline by Bioasis Technologies Inc, H2 2016 136 Glioblastoma Multiforme (GBM) - Pipeline by BioCancell Ltd, H2 2016 137 Glioblastoma Multiforme (GBM) - Pipeline by Biomar Microbial Technologies, H2 2016 138 Glioblastoma Multiforme (GBM) - Pipeline by Bioncotech Therapeutics SL, H2 2016 139 Glioblastoma Multiforme (GBM) - Pipeline by Biovista Inc, H2 2016 140 Glioblastoma Multiforme (GBM) - Pipeline by Boehringer Ingelheim GmbH, H2 2016 141 Glioblastoma Multiforme (GBM) - Pipeline by Boston Biomedical Inc, H2 2016 142 Glioblastoma Multiforme (GBM) - Pipeline by Bristol-Myers Squibb Company, H2 2016 143 Glioblastoma Multiforme (GBM) - Pipeline by BTG Plc, H2 2016 144 Glioblastoma Multiforme (GBM) - Pipeline by Cantex Pharmaceuticals Inc, H2 2016 145 Glioblastoma Multiforme (GBM) - Pipeline by Cavion LLC, H2 2016 146 Glioblastoma Multiforme (GBM) - Pipeline by Celgene Corp, H2 2016 147 Glioblastoma Multiforme (GBM) - Pipeline by Cell Medica Ltd, H2 2016 148 Glioblastoma Multiforme (GBM) - Pipeline by Celldex Therapeutics Inc, H2 2016 149 Glioblastoma Multiforme (GBM) - Pipeline by Celsion Corp, H2 2016 150 Glioblastoma Multiforme (GBM) - Pipeline by ChemoCentryx Inc, H2 2016 151 Glioblastoma Multiforme (GBM) - Pipeline by CLL Pharma SA, H2 2016 152 Glioblastoma Multiforme (GBM) - Pipeline by Coherus BioSciences Inc, H2 2016 153 Glioblastoma Multiforme (GBM) - Pipeline by Cortice Biosciences Inc, H2 2016 154 Glioblastoma Multiforme (GBM) - Pipeline by Critical Outcome Technologies Inc, H2 2016 155 Glioblastoma Multiforme (GBM) - Pipeline by CTI BioPharma Corp, H2 2016 156 Glioblastoma Multiforme (GBM) - Pipeline by Curadev Pharma Pvt Ltd, H2 2016 157 Glioblastoma Multiforme (GBM) - Pipeline by Cynata Therapeutics Limited, H2 2016 158 Glioblastoma Multiforme (GBM) - Pipeline by CytoVac A/S, H2 2016 159 Glioblastoma Multiforme (GBM) - Pipeline by CytRx Corp, H2 2016 160 Glioblastoma Multiforme (GBM) - Pipeline by Deciphera Pharmaceuticals LLC, H2 2016 161 Glioblastoma Multiforme (GBM) - Pipeline by DEKK-TEC Inc, H2 2016 162 Glioblastoma Multiforme (GBM) - Pipeline by DelMar Pharmaceuticals Inc, H2 2016 163 Glioblastoma Multiforme (GBM) - Pipeline by Diffusion Pharmaceuticals Inc, H2 2016 164 Glioblastoma Multiforme (GBM) - Pipeline by Dr. Reddy's Laboratories Ltd, H2 2016 165 Glioblastoma Multiforme (GBM) - Pipeline by Ecrins Therapeutics SAS, H2 2016 166 Glioblastoma Multiforme (GBM) - Pipeline by EirGenix Inc, H2 2016 167 Glioblastoma Multiforme (GBM) - Pipeline by Eisai Co Ltd, H2 2016 168 Glioblastoma Multiforme (GBM) - Pipeline by Eli Lilly and Company, H2 2016 169 Glioblastoma Multiforme (GBM) - Pipeline by EnGeneIC Ltd, H2 2016 170 Glioblastoma Multiforme (GBM) - Pipeline by EntreChem SL, H2 2016 171 Glioblastoma Multiforme (GBM) - Pipeline by ERC Belgium SA, H2 2016 172 Glioblastoma Multiforme (GBM) - Pipeline by Evotec AG, H2 2016 173 Glioblastoma Multiforme (GBM) - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 174 Glioblastoma Multiforme (GBM) - Pipeline by FirstString Research Inc, H2 2016 175 Glioblastoma Multiforme (GBM) - Pipeline by Five Prime Therapeutics Inc, H2 2016 176 Glioblastoma Multiforme (GBM) - Pipeline by Gene Techno Science Co Ltd, H2 2016 177 Glioblastoma Multiforme (GBM) - Pipeline by Genentech Inc, H2 2016 178 Glioblastoma Multiforme (GBM) - Pipeline by Genisphere Inc, H2 2016 179 Glioblastoma Multiforme (GBM) - Pipeline by Genor BioPharma Co Ltd, H2 2016 180 Glioblastoma Multiforme (GBM) - Pipeline by Genzyme Corp, H2 2016 181 Glioblastoma Multiforme (GBM) - Pipeline by GlaxoSmithKline Plc, H2 2016 182 Glioblastoma Multiforme (GBM) - Pipeline by GtreeBNT Co Ltd, H2 2016 183 Glioblastoma Multiforme (GBM) - Pipeline by GW Pharmaceuticals Plc, H2 2016 184 Glioblastoma Multiforme (GBM) - Pipeline by Hamlet Pharma AB, H2 2016 185 Glioblastoma Multiforme (GBM) - Pipeline by Hutchison MediPharma Ltd, H2 2016 186 Glioblastoma Multiforme (GBM) - Pipeline by Immatics Biotechnologies GmbH, H2 2016 187 Glioblastoma Multiforme (GBM) - Pipeline by Immune Pharmaceuticals Inc, H2 2016 188 Glioblastoma Multiforme (GBM) - Pipeline by ImmunoCellular Therapeutics Ltd, H2 2016 189 Glioblastoma Multiforme (GBM) - Pipeline by Immunomedics Inc, H2 2016 190 Glioblastoma Multiforme (GBM) - Pipeline by Immunomet Therapeutics Inc, H2 2016 191 Glioblastoma Multiforme (GBM) - Pipeline by Immunomic Therapeutics Inc, H2 2016 192 Glioblastoma Multiforme (GBM) - Pipeline by Immupharma Plc, H2 2016 193 Glioblastoma Multiforme (GBM) - Pipeline by Incuron LLC, H2 2016 194 Glioblastoma Multiforme (GBM) - Pipeline by Incyte Corp, H2 2016 195 Glioblastoma Multiforme (GBM) - Pipeline by Infinity Pharmaceuticals Inc, H2 2016 196 Glioblastoma Multiforme (GBM) - Pipeline by Inspyr Therapeutics Inc, H2 2016 197 Glioblastoma Multiforme (GBM) - Pipeline by INSYS Therapeutics Inc, H2 2016 198 Glioblastoma Multiforme (GBM) - Pipeline by Intica Biomedical Inc, H2 2016 199 Glioblastoma Multiforme (GBM) - Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, H2 2016 200 Glioblastoma Multiforme (GBM) - Pipeline by Johnson & Johnson, H2 2016 201 Glioblastoma Multiforme (GBM) - Pipeline by Kadmon Corp LLC, H2 2016 202 Glioblastoma Multiforme (GBM) - Pipeline by Kalgene Pharmaceuticals Inc, H2 2016 203 Glioblastoma Multiforme (GBM) - Pipeline by KaloBios Pharmaceuticals Inc, H2 2016 204 Glioblastoma Multiforme (GBM) - Pipeline by Karyopharm Therapeutics Inc, H2 2016 205 Glioblastoma Multiforme (GBM) - Pipeline by Kite Pharma Inc, H2 2016 206 Glioblastoma Multiforme (GBM) - Pipeline by Komipharm International Co Ltd, H2 2016 207 Glioblastoma Multiforme (GBM) - Pipeline by Lentigen Technology Inc, H2 2016 208 Glioblastoma Multiforme (GBM) - Pipeline by Les Laboratoires Servier SAS, H2 2016 209 Glioblastoma Multiforme (GBM) - Pipeline by LinXis BV, H2 2016 210 Glioblastoma Multiforme (GBM) - Pipeline by Lion Biotechnologies Inc, H2 2016 211 Glioblastoma Multiforme (GBM) - Pipeline by Lixte Biotechnology Holdings Inc, H2 2016 212 Glioblastoma Multiforme (GBM) - Pipeline by Loxo Oncology, Inc., H2 2016 213 Glioblastoma Multiforme (GBM) - Pipeline by Mabion SA, H2 2016 214 Glioblastoma Multiforme (GBM) - Pipeline by MacroGenics Inc, H2 2016 215 Glioblastoma Multiforme (GBM) - Pipeline by Mateon Therapeutics Inc, H2 2016 216 Glioblastoma Multiforme (GBM) - Pipeline by Medicenna Therapeutics Inc, H2 2016 217 Glioblastoma Multiforme (GBM) - Pipeline by MedImmune LLC, H2 2016 218 Glioblastoma Multiforme (GBM) - Pipeline by Merck & Co Inc, H2 2016 219 Glioblastoma Multiforme (GBM) - Pipeline by Merck KGaA, H2 2016 220 Glioblastoma Multiforme (GBM) - Pipeline by Midatech Pharma Plc, H2 2016 221 Glioblastoma Multiforme (GBM) - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 222 Glioblastoma Multiforme (GBM) - Pipeline by MimiVax LLC, H2 2016 223 Glioblastoma Multiforme (GBM) - Pipeline by Moleculin Biotech Inc, H2 2016 224 Glioblastoma Multiforme (GBM) - Pipeline by Mycenax Biotech Inc, H2 2016 225 Glioblastoma Multiforme (GBM) - Pipeline by Nanomerics Ltd, H2 2016 226 Glioblastoma Multiforme (GBM) - Pipeline by Neonc Technologies Inc, H2 2016 227 Glioblastoma Multiforme (GBM) - Pipeline by Nerviano Medical Sciences Srl, H2 2016 228 Glioblastoma Multiforme (GBM) - Pipeline by Neumedicines Inc, H2 2016 229 Glioblastoma Multiforme (GBM) - Pipeline by Neuralstem Inc, H2 2016 230 Glioblastoma Multiforme (GBM) - Pipeline by NewLink Genetics Corp, H2 2016 231 Glioblastoma Multiforme (GBM) - Pipeline by Northwest Biotherapeutics Inc, H2 2016 232 Glioblastoma Multiforme (GBM) - Pipeline by Novartis AG, H2 2016 233 Glioblastoma Multiforme (GBM) - Pipeline by Novogen Ltd, H2 2016 234 Glioblastoma Multiforme (GBM) - Pipeline by Noxxon Pharma AG, H2 2016 235 Glioblastoma Multiforme (GBM) - Pipeline by Nuo Therapeutics Inc, H2 2016 236 Glioblastoma Multiforme (GBM) - Pipeline by NuvOx Pharma LLC, H2 2016 237 Glioblastoma Multiforme (GBM) - Pipeline by Omniox Inc, H2 2016 238 Glioblastoma Multiforme (GBM) - Pipeline by Oncobiologics Inc, H2 2016 239 Glioblastoma Multiforme (GBM) - Pipeline by Oncodesign SA, H2 2016 240 Glioblastoma Multiforme (GBM) - Pipeline by Onconova Therapeutics Inc, H2 2016 241 Glioblastoma Multiforme (GBM) - Pipeline by Oncternal Therapeutics Inc, H2 2016 242 Glioblastoma Multiforme (GBM) - Pipeline by Ono Pharmaceutical Co Ltd, H2 2016 243 Glioblastoma Multiforme (GBM) - Pipeline by Orphagen Pharmaceuticals Inc, H2 2016 244 Glioblastoma Multiforme (GBM) - Pipeline by Orphit SAS, H2 2016 245 Glioblastoma Multiforme (GBM) - Pipeline by Oryx GmbH & Co KG, H2 2016 246 Glioblastoma Multiforme (GBM) - Pipeline by Peloton Therapeutics Inc, H2 2016 247 Glioblastoma Multiforme (GBM) - Pipeline by Peregrine Pharmaceuticals Inc, H2 2016 248 Glioblastoma Multiforme (GBM) - Pipeline by Pfizer Inc, H2 2016 249 Glioblastoma Multiforme (GBM) - Pipeline by PharmAbcine Inc, H2 2016 250 Glioblastoma Multiforme (GBM) - Pipeline by PharmaCyte Biotech Inc, H2 2016 251 Glioblastoma Multiforme (GBM) - Pipeline by Pharmicell Co Ltd, H2 2016 252 Glioblastoma Multiforme (GBM) - Pipeline by PIQUR Therapeutics AG, H2 2016 253 Glioblastoma Multiforme (GBM) - Pipeline by Plex Pharmaceuticals Inc, H2 2016 254 Glioblastoma Multiforme (GBM) - Pipeline by Plexxikon Inc, H2 2016 255 Glioblastoma Multiforme (GBM) - Pipeline by Prana Biotechnology Ltd, H2 2016 256 Glioblastoma Multiforme (GBM) - Pipeline by Progenics Pharmaceuticals Inc, H2 2016 257 Glioblastoma Multiforme (GBM) - Pipeline by Puma Biotechnology Inc, H2 2016 258 Glioblastoma Multiforme (GBM) - Pipeline by Recepta Biopharma SA, H2 2016 259 Glioblastoma Multiforme (GBM) - Pipeline by Regulus Therapeutics Inc, H2 2016 260 Glioblastoma Multiforme (GBM) - Pipeline by ReNeuron Group Plc, H2 2016 261 Glioblastoma Multiforme (GBM) - Pipeline by Rexahn Pharmaceuticals Inc, H2 2016 262 Glioblastoma Multiforme (GBM) - Pipeline by Rgenix Inc, H2 2016 263 Glioblastoma Multiforme (GBM) - Pipeline by Richter Gedeon Nyrt, H2 2016 264 Glioblastoma Multiforme (GBM) - Pipeline by Rigontec GmbH, H2 2016 265 Glioblastoma Multiforme (GBM) - Pipeline by Sanofi, H2 2016 266 Glioblastoma Multiforme (GBM) - Pipeline by Sapience Therapeutics Inc, H2 2016 267 Glioblastoma Multiforme (GBM) - Pipeline by Scancell Holdings Plc, H2 2016 268 Glioblastoma Multiforme (GBM) - Pipeline by Sellas Inc, H2 2016 269 Glioblastoma Multiforme (GBM) - Pipeline by Sigma-Tau SpA, H2 2016 270 Glioblastoma Multiforme (GBM) - Pipeline by SignPath Pharma Inc, H2 2016 271 Glioblastoma Multiforme (GBM) - Pipeline by SOM Biotech SL, H2 2016 272 Glioblastoma Multiforme (GBM) - Pipeline by Sorrento Therapeutics Inc, H2 2016 273 Glioblastoma Multiforme (GBM) - Pipeline by StemGen SpA, H2 2016 274 Glioblastoma Multiforme (GBM) - Pipeline by Stemline Therapeutics Inc, H2 2016 275 Glioblastoma Multiforme (GBM) - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2016 276 Glioblastoma Multiforme (GBM) - Pipeline by Susavion Biosciences Inc, H2 2016 277 Glioblastoma Multiforme (GBM) - Pipeline by Symphogen A/S, H2 2016 278 Glioblastoma Multiforme (GBM) - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2016 279 Glioblastoma Multiforme (GBM) - Pipeline by Terpenoid Therapeutics Inc, H2 2016 280 Glioblastoma Multiforme (GBM) - Pipeline by Therapeia GmbH & Co KG, H2 2016 281 Glioblastoma Multiforme (GBM) - Pipeline by Theravectys SA, H2 2016 282 Glioblastoma Multiforme (GBM) - Pipeline by Threshold Pharmaceuticals Inc, H2 2016 283 Glioblastoma Multiforme (GBM) - Pipeline by Tocagen Inc, H2 2016 284 Glioblastoma Multiforme (GBM) - Pipeline by TRACON Pharmaceuticals Inc, H2 2016 285 Glioblastoma Multiforme (GBM) - Pipeline by Transgene SA, H2 2016 286 Glioblastoma Multiforme (GBM) - Pipeline by Trillium Therapeutics Inc, H2 2016 287 Glioblastoma Multiforme (GBM) - Pipeline by TVAX Biomedical Inc, H2 2016 288 Glioblastoma Multiforme (GBM) - Pipeline by Tyme Technologies Inc, H2 2016 289 Glioblastoma Multiforme (GBM) - Pipeline by Upsher-Smith Laboratories Inc, H2 2016 290 Glioblastoma Multiforme (GBM) - Pipeline by Vascular Biogenics Ltd, H2 2016 291 Glioblastoma Multiforme (GBM) - Pipeline by Vault Pharma Inc, H2 2016 292 Glioblastoma Multiforme (GBM) - Pipeline by Vaximm AG, H2 2016 293 Glioblastoma Multiforme (GBM) - Pipeline by VBI Vaccines Inc, H2 2016 294 Glioblastoma Multiforme (GBM) - Pipeline by VCN Biosciences SL, H2 2016 295 Glioblastoma Multiforme (GBM) - Pipeline by Vertex Pharmaceuticals Inc, H2 2016 296 Glioblastoma Multiforme (GBM) - Pipeline by ViraTherapeutics GmbH, H2 2016 297 Glioblastoma Multiforme (GBM) - Pipeline by Virttu Biologics Ltd, H2 2016 298 Glioblastoma Multiforme (GBM) - Pipeline by Vyriad Inc, H2 2016 299 Glioblastoma Multiforme (GBM) - Pipeline by X4 Pharmaceuticals Inc, H2 2016 300 Glioblastoma Multiforme (GBM) - Pipeline by ZIOPHARM Oncology Inc, H2 2016 301 Assessment by Monotherapy Products, H2 2016 302 Assessment by Combination Products, H2 2016 303 Number of Products by Stage and Target, H2 2016 305 Number of Products by Stage and Mechanism of Action, H2 2016 323 Number of Products by Stage and Route of Administration, H2 2016 341 Number of Products by Stage and Molecule Type, H2 2016 343 Glioblastoma Multiforme (GBM) - Dormant Projects, H2 2016 1284 Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..1), H2 2016 1285 Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..2), H2 2016 1286 Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..3), H2 2016 1287 Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..4), H2 2016 1288 Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..5), H2 2016 1289 Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..6), H2 2016 1290 Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..7), H2 2016 1291 Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..8), H2 2016 1292 Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..9), H2 2016 1293 Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..10), H2 2016 1294 Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..11), H2 2016 1295 Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..12), H2 2016 1296 Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..13), H2 2016 1297 Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..14), H2 2016 1298 Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..15), H2 2016 1299 Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..16), H2 2016 1300 Glioblastoma Multiforme (GBM) - Discontinued Products, H2 2016 1301 Glioblastoma Multiforme (GBM) - Discontinued Products (Contd..1), H2 2016 1302 Glioblastoma Multiforme (GBM) - Discontinued Products (Contd..2), H2 2016 1303
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
